Ivor Douglas
Concepts (600)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Respiration, Artificial | 23 | 2024 | 529 | 3.960 |
Why?
| Sepsis | 19 | 2024 | 509 | 2.890 |
Why?
| Respiratory Insufficiency | 12 | 2023 | 290 | 2.420 |
Why?
| Fluid Therapy | 11 | 2024 | 123 | 2.360 |
Why?
| Critical Care | 18 | 2024 | 476 | 2.310 |
Why?
| Intensive Care Units | 23 | 2024 | 617 | 2.230 |
Why?
| Critical Illness | 20 | 2024 | 646 | 2.180 |
Why?
| Tracheostomy | 5 | 2024 | 101 | 1.860 |
Why?
| Shock, Septic | 11 | 2024 | 186 | 1.680 |
Why?
| Hospital Mortality | 19 | 2024 | 776 | 1.610 |
Why?
| Shock | 3 | 2024 | 84 | 1.480 |
Why?
| Hospitals | 6 | 2023 | 581 | 1.350 |
Why?
| Pneumonia | 7 | 2023 | 568 | 1.230 |
Why?
| Hypotension | 4 | 2024 | 116 | 1.050 |
Why?
| Resuscitation Orders | 3 | 2023 | 45 | 1.050 |
Why?
| Multiple Organ Failure | 4 | 2024 | 146 | 0.990 |
Why?
| Humans | 132 | 2025 | 114709 | 0.950 |
Why?
| Patient Readmission | 6 | 2021 | 610 | 0.920 |
Why?
| Vasoconstrictor Agents | 5 | 2023 | 113 | 0.890 |
Why?
| Middle Aged | 55 | 2025 | 26738 | 0.890 |
Why?
| Ultrasonography, Doppler | 1 | 2024 | 105 | 0.870 |
Why?
| Aged | 42 | 2025 | 19074 | 0.860 |
Why?
| Pneumonia, Ventilator-Associated | 2 | 2015 | 40 | 0.840 |
Why?
| Resuscitation | 8 | 2024 | 252 | 0.790 |
Why?
| Safety-net Providers | 3 | 2023 | 95 | 0.790 |
Why?
| Hemodynamics | 3 | 2024 | 1012 | 0.780 |
Why?
| Extracorporeal Membrane Oxygenation | 2 | 2023 | 241 | 0.770 |
Why?
| Severity of Illness Index | 6 | 2021 | 2540 | 0.770 |
Why?
| Hospitals, High-Volume | 2 | 2019 | 39 | 0.770 |
Why?
| Retrospective Studies | 30 | 2024 | 12556 | 0.760 |
Why?
| Patient Acceptance of Health Care | 5 | 2021 | 681 | 0.740 |
Why?
| Male | 70 | 2025 | 55609 | 0.740 |
Why?
| Monitoring, Physiologic | 4 | 2024 | 249 | 0.740 |
Why?
| Frailty | 1 | 2023 | 115 | 0.730 |
Why?
| Patient Positioning | 1 | 2021 | 42 | 0.720 |
Why?
| Diabetes Insipidus | 1 | 2020 | 7 | 0.700 |
Why?
| Practice Guidelines as Topic | 6 | 2021 | 1395 | 0.690 |
Why?
| Substance Withdrawal Syndrome | 3 | 2021 | 159 | 0.650 |
Why?
| Hospitals, Low-Volume | 1 | 2019 | 22 | 0.640 |
Why?
| Adult | 43 | 2025 | 30554 | 0.630 |
Why?
| Female | 61 | 2025 | 59523 | 0.620 |
Why?
| Dyspnea | 2 | 2021 | 211 | 0.620 |
Why?
| Diabetes Mellitus | 2 | 2020 | 900 | 0.590 |
Why?
| Alcoholism | 5 | 2021 | 713 | 0.560 |
Why?
| Ventilator-Induced Lung Injury | 3 | 2018 | 49 | 0.550 |
Why?
| California | 5 | 2022 | 353 | 0.540 |
Why?
| Neoplasms | 3 | 2023 | 2097 | 0.540 |
Why?
| Randomized Controlled Trials as Topic | 11 | 2024 | 1214 | 0.540 |
Why?
| Pulmonary Medicine | 3 | 2015 | 87 | 0.520 |
Why?
| Microbiological Techniques | 1 | 2016 | 29 | 0.520 |
Why?
| Sleep Medicine Specialty | 1 | 2015 | 9 | 0.510 |
Why?
| Acute Kidney Injury | 7 | 2023 | 638 | 0.500 |
Why?
| Acute Lung Injury | 6 | 2023 | 299 | 0.490 |
Why?
| Ethanol | 2 | 2021 | 538 | 0.490 |
Why?
| Molecular Diagnostic Techniques | 1 | 2016 | 92 | 0.490 |
Why?
| Health Policy | 4 | 2024 | 334 | 0.490 |
Why?
| Hyperemia | 3 | 2024 | 45 | 0.480 |
Why?
| Research Design | 9 | 2023 | 928 | 0.470 |
Why?
| Cohort Studies | 11 | 2023 | 4895 | 0.460 |
Why?
| Aged, 80 and over | 12 | 2025 | 6347 | 0.450 |
Why?
| Pulmonary Disease, Chronic Obstructive | 7 | 2017 | 916 | 0.440 |
Why?
| Renin-Angiotensin System | 2 | 2025 | 72 | 0.440 |
Why?
| Prone Position | 3 | 2021 | 27 | 0.430 |
Why?
| Bronchoalveolar Lavage Fluid | 2 | 2016 | 590 | 0.430 |
Why?
| Inpatients | 3 | 2023 | 380 | 0.430 |
Why?
| Receptor, EphA2 | 3 | 2018 | 19 | 0.430 |
Why?
| Cause of Death | 3 | 2015 | 361 | 0.420 |
Why?
| Immune Tolerance | 1 | 2015 | 323 | 0.420 |
Why?
| Nicotinic Agonists | 1 | 2014 | 100 | 0.410 |
Why?
| Laryngoscopes | 2 | 2023 | 38 | 0.410 |
Why?
| Dual Specificity Phosphatase 1 | 1 | 2012 | 28 | 0.400 |
Why?
| Cross Infection | 5 | 2020 | 197 | 0.400 |
Why?
| Noninvasive Ventilation | 3 | 2017 | 32 | 0.400 |
Why?
| Marijuana Smoking | 1 | 2015 | 224 | 0.400 |
Why?
| Lung | 12 | 2018 | 3561 | 0.400 |
Why?
| Apoptosis | 6 | 2014 | 2363 | 0.390 |
Why?
| Pulmonary Fibrosis | 4 | 2017 | 323 | 0.390 |
Why?
| Hospitalization | 9 | 2025 | 1752 | 0.390 |
Why?
| Immunity, Innate | 1 | 2017 | 720 | 0.380 |
Why?
| Tobacco Use Disorder | 1 | 2014 | 234 | 0.380 |
Why?
| Prospective Studies | 12 | 2024 | 6220 | 0.380 |
Why?
| Nicotine | 1 | 2014 | 265 | 0.380 |
Why?
| Lipopolysaccharides | 4 | 2017 | 823 | 0.380 |
Why?
| Organ Dysfunction Scores | 2 | 2024 | 39 | 0.370 |
Why?
| Drug Delivery Systems | 1 | 2014 | 296 | 0.370 |
Why?
| Child Development | 1 | 2015 | 385 | 0.370 |
Why?
| Protein C | 5 | 2012 | 45 | 0.360 |
Why?
| Tissue Plasminogen Activator | 2 | 2024 | 225 | 0.360 |
Why?
| Delirium | 2 | 2024 | 66 | 0.360 |
Why?
| Glycosaminoglycans | 3 | 2016 | 79 | 0.360 |
Why?
| Long-Term Care | 2 | 2022 | 78 | 0.350 |
Why?
| Emergency Service, Hospital | 5 | 2024 | 1820 | 0.350 |
Why?
| United States | 18 | 2024 | 12186 | 0.340 |
Why?
| Length of Stay | 6 | 2024 | 962 | 0.340 |
Why?
| Smoking Cessation | 1 | 2014 | 374 | 0.340 |
Why?
| Treatment Outcome | 15 | 2024 | 9088 | 0.340 |
Why?
| Antipsychotic Agents | 2 | 2024 | 184 | 0.330 |
Why?
| Public Health | 1 | 2014 | 434 | 0.330 |
Why?
| Comorbidity | 4 | 2022 | 1448 | 0.330 |
Why?
| Metabolic Syndrome | 2 | 2023 | 321 | 0.330 |
Why?
| Vena Cava, Inferior | 3 | 2024 | 56 | 0.320 |
Why?
| Cannabis | 1 | 2015 | 384 | 0.320 |
Why?
| Ephrin-A1 | 3 | 2018 | 4 | 0.320 |
Why?
| Biomarkers | 7 | 2023 | 3408 | 0.320 |
Why?
| Intubation, Intratracheal | 4 | 2024 | 216 | 0.310 |
Why?
| Lipid A | 2 | 2014 | 28 | 0.310 |
Why?
| Societies, Medical | 7 | 2021 | 664 | 0.310 |
Why?
| Institutional Practice | 1 | 2008 | 3 | 0.310 |
Why?
| Anti-Bacterial Agents | 1 | 2017 | 1481 | 0.300 |
Why?
| Odds Ratio | 6 | 2019 | 953 | 0.300 |
Why?
| Personnel Staffing and Scheduling | 1 | 2008 | 79 | 0.290 |
Why?
| Pandemics | 4 | 2024 | 1320 | 0.290 |
Why?
| Betacoronavirus | 2 | 2020 | 250 | 0.290 |
Why?
| Neutrophils | 3 | 2024 | 1176 | 0.290 |
Why?
| Integrins | 1 | 2007 | 79 | 0.280 |
Why?
| Pulmonary Alveolar Proteinosis | 1 | 2007 | 16 | 0.280 |
Why?
| Neovascularization, Pathologic | 2 | 2007 | 281 | 0.280 |
Why?
| Renal Insufficiency, Chronic | 2 | 2024 | 486 | 0.280 |
Why?
| MAP Kinase Signaling System | 2 | 2014 | 276 | 0.270 |
Why?
| Lung Injury | 3 | 2016 | 198 | 0.270 |
Why?
| Patient Admission | 2 | 2023 | 176 | 0.270 |
Why?
| Ultrasonography | 3 | 2024 | 634 | 0.270 |
Why?
| Hyponatremia | 1 | 2006 | 37 | 0.260 |
Why?
| Double-Blind Method | 9 | 2024 | 1660 | 0.260 |
Why?
| Lung Diseases, Obstructive | 1 | 2006 | 40 | 0.260 |
Why?
| Leukocytes | 1 | 2007 | 276 | 0.260 |
Why?
| Medicaid | 3 | 2021 | 407 | 0.250 |
Why?
| Treatment Failure | 7 | 2024 | 331 | 0.250 |
Why?
| Biomedical Research | 3 | 2021 | 585 | 0.250 |
Why?
| Pneumonia, Viral | 2 | 2020 | 338 | 0.250 |
Why?
| Coronavirus Infections | 2 | 2020 | 330 | 0.250 |
Why?
| Laryngoscopy | 2 | 2023 | 91 | 0.250 |
Why?
| Academic Medical Centers | 3 | 2021 | 411 | 0.250 |
Why?
| Chemokines, CXC | 1 | 2005 | 60 | 0.240 |
Why?
| Bronchi | 1 | 2006 | 232 | 0.240 |
Why?
| Regeneration | 1 | 2006 | 160 | 0.240 |
Why?
| Bronchiectasis | 1 | 2006 | 106 | 0.240 |
Why?
| Oxazines | 1 | 2024 | 25 | 0.240 |
Why?
| Bronchiolitis Obliterans | 1 | 2005 | 66 | 0.240 |
Why?
| Succinylcholine | 1 | 2024 | 7 | 0.240 |
Why?
| Adrenal Insufficiency | 2 | 2013 | 26 | 0.240 |
Why?
| Infusions, Intravenous | 5 | 2024 | 371 | 0.240 |
Why?
| Methylprednisolone | 1 | 2005 | 81 | 0.230 |
Why?
| Hypoxia | 3 | 2024 | 958 | 0.230 |
Why?
| Respiratory Mucosa | 1 | 2006 | 251 | 0.230 |
Why?
| Venous Pressure | 1 | 2024 | 8 | 0.230 |
Why?
| Phagocytosis | 1 | 2006 | 350 | 0.230 |
Why?
| Patient Protection and Affordable Care Act | 2 | 2016 | 99 | 0.230 |
Why?
| Cytokines | 7 | 2017 | 1841 | 0.230 |
Why?
| Risk Factors | 10 | 2021 | 8634 | 0.230 |
Why?
| Morpholines | 1 | 2024 | 102 | 0.230 |
Why?
| Plasminogen | 1 | 2024 | 33 | 0.230 |
Why?
| Vasopressins | 3 | 2021 | 56 | 0.230 |
Why?
| Anti-Infective Agents | 4 | 2012 | 225 | 0.220 |
Why?
| Leukocyte Elastase | 1 | 2024 | 80 | 0.220 |
Why?
| Renal Dialysis | 4 | 2023 | 374 | 0.220 |
Why?
| beta Catenin | 1 | 2005 | 219 | 0.220 |
Why?
| Plasminogen Activator Inhibitor 1 | 1 | 2024 | 83 | 0.220 |
Why?
| Atrial Pressure | 1 | 2023 | 4 | 0.220 |
Why?
| Receptor, Angiotensin, Type 1 | 1 | 2023 | 20 | 0.220 |
Why?
| Diterpenes | 2 | 2014 | 31 | 0.210 |
Why?
| Craniocerebral Trauma | 1 | 2005 | 134 | 0.210 |
Why?
| Area Under Curve | 3 | 2020 | 274 | 0.210 |
Why?
| Lung Diseases | 3 | 2016 | 701 | 0.210 |
Why?
| Haloperidol | 2 | 2024 | 35 | 0.210 |
Why?
| Analgesics, Non-Narcotic | 1 | 2024 | 120 | 0.210 |
Why?
| Hemodynamic Monitoring | 1 | 2022 | 1 | 0.210 |
Why?
| Fibrosis | 1 | 2005 | 453 | 0.210 |
Why?
| Thiazoles | 2 | 2024 | 110 | 0.210 |
Why?
| Fibrinolysis | 1 | 2024 | 158 | 0.200 |
Why?
| Evidence-Based Medicine | 5 | 2016 | 668 | 0.190 |
Why?
| Clinical Decision-Making | 1 | 2024 | 268 | 0.190 |
Why?
| Early Diagnosis | 4 | 2017 | 217 | 0.190 |
Why?
| Transportation | 1 | 2022 | 44 | 0.190 |
Why?
| Acetaminophen | 1 | 2024 | 241 | 0.190 |
Why?
| Hydrocortisone | 1 | 2003 | 267 | 0.190 |
Why?
| Logistic Models | 7 | 2017 | 1841 | 0.190 |
Why?
| Pyridines | 1 | 2024 | 425 | 0.190 |
Why?
| Stroke Volume | 1 | 2024 | 504 | 0.190 |
Why?
| Vasodilator Agents | 1 | 2023 | 302 | 0.190 |
Why?
| Heart Arrest | 2 | 2021 | 293 | 0.180 |
Why?
| Receptors, Interleukin-6 | 1 | 2021 | 34 | 0.180 |
Why?
| Central Nervous System Depressants | 1 | 2021 | 81 | 0.180 |
Why?
| Piperazines | 2 | 2024 | 309 | 0.180 |
Why?
| Internship and Residency | 2 | 2019 | 926 | 0.180 |
Why?
| Hospital Charges | 1 | 2020 | 39 | 0.180 |
Why?
| Animals | 20 | 2018 | 31709 | 0.180 |
Why?
| Community-Acquired Infections | 3 | 2020 | 141 | 0.180 |
Why?
| Reproducibility of Results | 5 | 2024 | 2765 | 0.180 |
Why?
| Rib Fractures | 1 | 2020 | 25 | 0.180 |
Why?
| Health Priorities | 1 | 2020 | 34 | 0.180 |
Why?
| Glucocorticoids | 1 | 2005 | 532 | 0.180 |
Why?
| Hydroxychloroquine | 1 | 2020 | 54 | 0.180 |
Why?
| Heart Failure | 3 | 2023 | 1945 | 0.170 |
Why?
| Cell Proliferation | 2 | 2014 | 2187 | 0.170 |
Why?
| Mice, Inbred C57BL | 9 | 2018 | 4694 | 0.170 |
Why?
| Antigens, Differentiation | 1 | 2000 | 79 | 0.170 |
Why?
| Patient Selection | 1 | 2023 | 641 | 0.170 |
Why?
| Patient Handoff | 1 | 2019 | 26 | 0.170 |
Why?
| Risk Adjustment | 1 | 2020 | 76 | 0.160 |
Why?
| Age Factors | 4 | 2019 | 2894 | 0.160 |
Why?
| Blood Glucose Self-Monitoring | 1 | 2023 | 506 | 0.160 |
Why?
| Cell Adhesion Molecules | 1 | 2000 | 168 | 0.160 |
Why?
| Hospital Costs | 1 | 2019 | 104 | 0.160 |
Why?
| Combined Modality Therapy | 2 | 2020 | 1121 | 0.160 |
Why?
| Dopamine Antagonists | 1 | 2018 | 22 | 0.160 |
Why?
| Health Services Accessibility | 4 | 2020 | 763 | 0.160 |
Why?
| ROC Curve | 1 | 2020 | 442 | 0.150 |
Why?
| Thrombosis | 1 | 2021 | 298 | 0.150 |
Why?
| Orthopedic Procedures | 1 | 2020 | 208 | 0.150 |
Why?
| Antimicrobial Stewardship | 1 | 2020 | 94 | 0.150 |
Why?
| Blood Glucose | 2 | 2023 | 1829 | 0.150 |
Why?
| Eosinophils | 1 | 2000 | 278 | 0.150 |
Why?
| Predictive Value of Tests | 4 | 2016 | 1796 | 0.150 |
Why?
| Optometry | 1 | 2017 | 2 | 0.150 |
Why?
| Mice | 13 | 2017 | 14872 | 0.140 |
Why?
| Guideline Adherence | 2 | 2014 | 490 | 0.140 |
Why?
| Platelet Count | 2 | 2014 | 81 | 0.140 |
Why?
| Tidal Volume | 2 | 2014 | 75 | 0.140 |
Why?
| Cell Adhesion | 4 | 2012 | 432 | 0.140 |
Why?
| Pyrimidines | 2 | 2024 | 376 | 0.140 |
Why?
| Lymphocyte Count | 1 | 2017 | 133 | 0.140 |
Why?
| Cystic Fibrosis | 1 | 2006 | 955 | 0.140 |
Why?
| Analysis of Variance | 1 | 2020 | 1226 | 0.140 |
Why?
| Transients and Migrants | 1 | 2017 | 22 | 0.140 |
Why?
| Attitude of Health Personnel | 3 | 2019 | 975 | 0.140 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 663 | 0.130 |
Why?
| Delivery of Health Care | 1 | 2023 | 833 | 0.130 |
Why?
| Tretinoin | 1 | 2017 | 122 | 0.130 |
Why?
| Clinical Trials as Topic | 1 | 2021 | 932 | 0.130 |
Why?
| Burnout, Professional | 1 | 2021 | 322 | 0.130 |
Why?
| Nephrectomy | 2 | 2008 | 150 | 0.130 |
Why?
| Ventricular Function, Right | 1 | 2018 | 250 | 0.130 |
Why?
| Continuity of Patient Care | 1 | 2018 | 253 | 0.130 |
Why?
| Health Insurance Exchanges | 1 | 2016 | 2 | 0.130 |
Why?
| Sleep Wake Disorders | 2 | 2017 | 233 | 0.130 |
Why?
| Risk Management | 1 | 2017 | 89 | 0.130 |
Why?
| Breath Tests | 1 | 2016 | 82 | 0.130 |
Why?
| Ventricular Dysfunction, Right | 1 | 2018 | 217 | 0.130 |
Why?
| Staphylococcus aureus | 2 | 2011 | 389 | 0.130 |
Why?
| Respiratory Tract Diseases | 1 | 2017 | 138 | 0.120 |
Why?
| Prognosis | 5 | 2021 | 3330 | 0.120 |
Why?
| Quality of Life | 2 | 2024 | 2353 | 0.120 |
Why?
| Research | 1 | 2018 | 394 | 0.120 |
Why?
| Patient Care Team | 1 | 2019 | 517 | 0.120 |
Why?
| Survival Analysis | 4 | 2014 | 1211 | 0.120 |
Why?
| Marriage | 1 | 2016 | 106 | 0.120 |
Why?
| Alcohol Withdrawal Seizures | 1 | 2014 | 1 | 0.120 |
Why?
| Risk Assessment | 5 | 2015 | 2968 | 0.120 |
Why?
| Bronchoalveolar Lavage | 1 | 2015 | 84 | 0.120 |
Why?
| Alcohol Withdrawal Delirium | 1 | 2014 | 8 | 0.120 |
Why?
| Automation | 1 | 2015 | 74 | 0.120 |
Why?
| Multicenter Studies as Topic | 3 | 2023 | 249 | 0.120 |
Why?
| Bacteriological Techniques | 1 | 2015 | 65 | 0.120 |
Why?
| Physicians | 2 | 2021 | 772 | 0.120 |
Why?
| 5-Lipoxygenase-Activating Protein Inhibitors | 1 | 2014 | 1 | 0.120 |
Why?
| 5-Lipoxygenase-Activating Proteins | 1 | 2014 | 5 | 0.120 |
Why?
| Education, Medical | 1 | 2017 | 215 | 0.120 |
Why?
| Catheterization, Central Venous | 1 | 2015 | 83 | 0.120 |
Why?
| Fluorobenzenes | 1 | 2014 | 11 | 0.120 |
Why?
| Leukotrienes | 1 | 2014 | 35 | 0.120 |
Why?
| Phenanthrenes | 1 | 2014 | 10 | 0.120 |
Why?
| Poverty | 2 | 2016 | 442 | 0.110 |
Why?
| APACHE | 2 | 2011 | 58 | 0.110 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2000 | 959 | 0.110 |
Why?
| Down-Regulation | 2 | 2017 | 594 | 0.110 |
Why?
| Potassium | 1 | 2014 | 128 | 0.110 |
Why?
| Alanine Transaminase | 1 | 2014 | 142 | 0.110 |
Why?
| Systemic Inflammatory Response Syndrome | 1 | 2014 | 72 | 0.110 |
Why?
| Microscopy | 1 | 2015 | 125 | 0.110 |
Why?
| Kaplan-Meier Estimate | 5 | 2018 | 811 | 0.110 |
Why?
| Angiotensin II | 2 | 2025 | 87 | 0.110 |
Why?
| Laryngeal Masks | 1 | 2013 | 13 | 0.110 |
Why?
| Quinolines | 1 | 2014 | 129 | 0.110 |
Why?
| Time Factors | 7 | 2023 | 6116 | 0.100 |
Why?
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 1183 | 0.100 |
Why?
| Patient Discharge | 1 | 2018 | 773 | 0.100 |
Why?
| Sensitivity and Specificity | 2 | 2015 | 1694 | 0.100 |
Why?
| Cisplatin | 1 | 2014 | 262 | 0.100 |
Why?
| Physician-Patient Relations | 1 | 2017 | 462 | 0.100 |
Why?
| Glycocalyx | 1 | 2012 | 18 | 0.100 |
Why?
| Patient-Centered Care | 1 | 2017 | 473 | 0.100 |
Why?
| Acute Disease | 3 | 2016 | 911 | 0.100 |
Why?
| Oxygen | 3 | 2023 | 854 | 0.100 |
Why?
| Follow-Up Studies | 5 | 2024 | 4411 | 0.100 |
Why?
| Supine Position | 1 | 2012 | 32 | 0.100 |
Why?
| Indoles | 1 | 2014 | 304 | 0.100 |
Why?
| Insurance, Health | 1 | 2014 | 244 | 0.100 |
Why?
| Biomarkers, Pharmacological | 1 | 2012 | 26 | 0.100 |
Why?
| Data Interpretation, Statistical | 2 | 2011 | 321 | 0.100 |
Why?
| I-kappa B Proteins | 1 | 2012 | 79 | 0.100 |
Why?
| Health Status | 1 | 2017 | 722 | 0.100 |
Why?
| Clinical Alarms | 1 | 2011 | 10 | 0.100 |
Why?
| Data Display | 1 | 2011 | 19 | 0.100 |
Why?
| Endotoxemia | 1 | 2012 | 86 | 0.090 |
Why?
| Adrenergic beta-2 Receptor Agonists | 1 | 2011 | 32 | 0.090 |
Why?
| Albuterol | 1 | 2011 | 102 | 0.090 |
Why?
| Genetic Markers | 1 | 2012 | 320 | 0.090 |
Why?
| Sulfonamides | 1 | 2014 | 445 | 0.090 |
Why?
| Fibrinolytic Agents | 2 | 2024 | 234 | 0.090 |
Why?
| Decision Making | 1 | 2017 | 782 | 0.090 |
Why?
| Interferons | 1 | 2011 | 151 | 0.090 |
Why?
| Peroxidase | 2 | 2008 | 163 | 0.090 |
Why?
| Alcohol-Related Disorders | 1 | 2011 | 113 | 0.090 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 373 | 0.090 |
Why?
| Recombinant Proteins | 5 | 2012 | 1230 | 0.090 |
Why?
| Survival Rate | 3 | 2015 | 1644 | 0.090 |
Why?
| Stenotrophomonas maltophilia | 1 | 2009 | 2 | 0.090 |
Why?
| Disease Models, Animal | 5 | 2018 | 3535 | 0.090 |
Why?
| Clinical Protocols | 2 | 2012 | 233 | 0.080 |
Why?
| Thoracic Diseases | 1 | 2009 | 13 | 0.080 |
Why?
| Databases, Factual | 2 | 2016 | 1125 | 0.080 |
Why?
| Cell Movement | 3 | 2011 | 869 | 0.080 |
Why?
| Ligands | 2 | 2023 | 562 | 0.080 |
Why?
| Adrenal Cortex Hormones | 1 | 2013 | 497 | 0.080 |
Why?
| Gram-Negative Bacterial Infections | 1 | 2009 | 37 | 0.080 |
Why?
| Symptom Assessment | 2 | 2020 | 119 | 0.080 |
Why?
| Blotting, Western | 1 | 2012 | 1147 | 0.080 |
Why?
| Polymerase Chain Reaction | 1 | 2012 | 993 | 0.080 |
Why?
| Cues | 1 | 2011 | 300 | 0.080 |
Why?
| Up-Regulation | 1 | 2012 | 808 | 0.080 |
Why?
| Confidence Intervals | 1 | 2010 | 305 | 0.080 |
Why?
| Age Distribution | 1 | 2010 | 342 | 0.080 |
Why?
| Wounds and Injuries | 1 | 2016 | 749 | 0.080 |
Why?
| Sex Distribution | 1 | 2010 | 337 | 0.080 |
Why?
| Pancreatitis | 1 | 2009 | 107 | 0.080 |
Why?
| Healthcare Disparities | 1 | 2014 | 480 | 0.080 |
Why?
| Pneumonia, Bacterial | 1 | 2009 | 106 | 0.080 |
Why?
| Pulmonary Alveoli | 2 | 2012 | 373 | 0.080 |
Why?
| Incidence | 1 | 2014 | 2313 | 0.080 |
Why?
| Models, Statistical | 1 | 2012 | 599 | 0.080 |
Why?
| Work Schedule Tolerance | 1 | 2008 | 35 | 0.080 |
Why?
| Clinical Trials, Phase III as Topic | 2 | 2023 | 82 | 0.070 |
Why?
| Child, Preschool | 2 | 2015 | 9119 | 0.070 |
Why?
| United Kingdom | 1 | 2008 | 226 | 0.070 |
Why?
| Disease Progression | 4 | 2017 | 2381 | 0.070 |
Why?
| Clinical Competence | 1 | 2014 | 893 | 0.070 |
Why?
| Interleukin-6 | 2 | 2008 | 676 | 0.070 |
Why?
| Signal Transduction | 4 | 2018 | 4516 | 0.070 |
Why?
| Rats, Sprague-Dawley | 1 | 2012 | 2218 | 0.070 |
Why?
| Workload | 1 | 2008 | 132 | 0.070 |
Why?
| Flavonoids | 1 | 2007 | 66 | 0.070 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 1995 | 961 | 0.070 |
Why?
| Mandatory Programs | 1 | 2007 | 15 | 0.070 |
Why?
| Pulmonary Emphysema | 2 | 2007 | 272 | 0.070 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2024 | 797 | 0.070 |
Why?
| Adolescent | 5 | 2025 | 17855 | 0.070 |
Why?
| Demeclocycline | 1 | 2006 | 3 | 0.070 |
Why?
| Mice, Inbred C3H | 1 | 2007 | 239 | 0.070 |
Why?
| Young Adult | 5 | 2025 | 10472 | 0.070 |
Why?
| Methicillin Resistance | 1 | 2006 | 18 | 0.070 |
Why?
| Lithium Compounds | 1 | 2006 | 9 | 0.070 |
Why?
| Sex Factors | 3 | 2018 | 1715 | 0.070 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2007 | 146 | 0.070 |
Why?
| Mitogen-Activated Protein Kinase 1 | 1 | 2007 | 164 | 0.070 |
Why?
| Rats | 2 | 2012 | 4958 | 0.070 |
Why?
| Diuretics | 1 | 2006 | 66 | 0.070 |
Why?
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2006 | 97 | 0.070 |
Why?
| Hospitals, Urban | 2 | 2018 | 127 | 0.070 |
Why?
| Mesoderm | 1 | 2007 | 138 | 0.070 |
Why?
| Protein Kinase Inhibitors | 2 | 2024 | 785 | 0.070 |
Why?
| Hospital Information Systems | 1 | 2006 | 13 | 0.070 |
Why?
| History, 20th Century | 2 | 2017 | 264 | 0.070 |
Why?
| Hypertension, Pulmonary | 2 | 2007 | 1729 | 0.070 |
Why?
| Intercellular Adhesion Molecule-1 | 2 | 2012 | 154 | 0.060 |
Why?
| Mice, Inbred BALB C | 2 | 2005 | 1144 | 0.060 |
Why?
| Radiography, Thoracic | 1 | 2007 | 150 | 0.060 |
Why?
| Occupational Health | 1 | 2008 | 165 | 0.060 |
Why?
| Heparin | 1 | 2007 | 224 | 0.060 |
Why?
| Butylated Hydroxytoluene | 1 | 2005 | 31 | 0.060 |
Why?
| Asparagine | 1 | 2005 | 29 | 0.060 |
Why?
| Vocabulary | 1 | 2006 | 41 | 0.060 |
Why?
| Gene Expression Profiling | 1 | 2012 | 1518 | 0.060 |
Why?
| Gene Expression Regulation | 2 | 2012 | 2320 | 0.060 |
Why?
| Cyclin D1 | 1 | 2005 | 61 | 0.060 |
Why?
| Emphysema | 1 | 2006 | 107 | 0.060 |
Why?
| Venous Thrombosis | 1 | 2007 | 140 | 0.060 |
Why?
| Cell Line, Transformed | 1 | 2005 | 133 | 0.060 |
Why?
| Medical Order Entry Systems | 1 | 2006 | 41 | 0.060 |
Why?
| Blood Vessels | 1 | 2007 | 180 | 0.060 |
Why?
| Caspase Inhibitors | 1 | 2005 | 78 | 0.060 |
Why?
| Macrophages | 2 | 2014 | 1263 | 0.060 |
Why?
| Angiotensin I | 1 | 2025 | 5 | 0.060 |
Why?
| Ischemia | 1 | 2008 | 362 | 0.060 |
Why?
| Bronchoscopy | 1 | 2007 | 245 | 0.060 |
Why?
| Necrosis | 1 | 2005 | 211 | 0.060 |
Why?
| Androstanols | 1 | 2024 | 5 | 0.060 |
Why?
| Neuromuscular Depolarizing Agents | 1 | 2024 | 5 | 0.060 |
Why?
| Neuromuscular Nondepolarizing Agents | 1 | 2024 | 8 | 0.060 |
Why?
| Colorado | 4 | 2017 | 4100 | 0.060 |
Why?
| HMGB1 Protein | 1 | 2005 | 48 | 0.060 |
Why?
| Diabetic Ketoacidosis | 1 | 2007 | 160 | 0.060 |
Why?
| Hope | 1 | 2024 | 13 | 0.060 |
Why?
| Neuromuscular Blocking Agents | 1 | 2024 | 24 | 0.060 |
Why?
| Pyridazines | 1 | 2024 | 46 | 0.060 |
Why?
| Caspases | 1 | 2005 | 245 | 0.060 |
Why?
| Cadherins | 1 | 2005 | 175 | 0.060 |
Why?
| Practice Patterns, Physicians' | 3 | 2024 | 1177 | 0.060 |
Why?
| T-Lymphocyte Subsets | 1 | 2006 | 383 | 0.060 |
Why?
| Renal Replacement Therapy | 1 | 2024 | 66 | 0.060 |
Why?
| Mental Health | 2 | 2022 | 562 | 0.060 |
Why?
| Medicago | 1 | 2023 | 1 | 0.060 |
Why?
| Steroids | 2 | 2021 | 144 | 0.060 |
Why?
| Uncertainty | 1 | 2024 | 95 | 0.060 |
Why?
| Pleural Effusion | 1 | 2024 | 47 | 0.060 |
Why?
| Enzyme Inhibitors | 1 | 2007 | 750 | 0.060 |
Why?
| Atrial Function, Right | 1 | 2023 | 12 | 0.050 |
Why?
| Angiotensins | 1 | 2023 | 10 | 0.050 |
Why?
| Inflammatory Bowel Diseases | 1 | 2007 | 284 | 0.050 |
Why?
| Autoimmune Diseases | 1 | 2006 | 382 | 0.050 |
Why?
| Collagen | 1 | 2005 | 415 | 0.050 |
Why?
| Antineoplastic Agents | 1 | 2014 | 1879 | 0.050 |
Why?
| Multivariate Analysis | 2 | 2017 | 1430 | 0.050 |
Why?
| Heparitin Sulfate | 2 | 2014 | 39 | 0.050 |
Why?
| Biopsy | 1 | 2007 | 1036 | 0.050 |
Why?
| Drug Administration Schedule | 2 | 2018 | 718 | 0.050 |
Why?
| Decision Support Techniques | 2 | 2020 | 355 | 0.050 |
Why?
| Anticoagulants | 1 | 2007 | 550 | 0.050 |
Why?
| Homeostasis | 1 | 2006 | 573 | 0.050 |
Why?
| Child | 2 | 2015 | 18422 | 0.050 |
Why?
| Diagnosis, Differential | 1 | 2007 | 1342 | 0.050 |
Why?
| Lung Neoplasms | 1 | 1995 | 2177 | 0.050 |
Why?
| Video Recording | 1 | 2023 | 143 | 0.050 |
Why?
| Staphylococcal Infections | 1 | 2006 | 340 | 0.050 |
Why?
| Hemoglobins | 1 | 2024 | 315 | 0.050 |
Why?
| Infant | 1 | 2015 | 7964 | 0.050 |
Why?
| Creatinine | 2 | 2015 | 425 | 0.050 |
Why?
| Endothelial Cells | 1 | 2007 | 687 | 0.050 |
Why?
| p38 Mitogen-Activated Protein Kinases | 2 | 2014 | 260 | 0.050 |
Why?
| Partial Thromboplastin Time | 1 | 2021 | 51 | 0.050 |
Why?
| Lung Diseases, Interstitial | 1 | 2007 | 508 | 0.050 |
Why?
| Oligopeptides | 1 | 2023 | 236 | 0.050 |
Why?
| Perioperative Care | 1 | 2022 | 127 | 0.050 |
Why?
| Electrocardiography | 1 | 2024 | 560 | 0.050 |
Why?
| Peptide Fragments | 1 | 2025 | 666 | 0.050 |
Why?
| Antibodies | 2 | 2018 | 371 | 0.050 |
Why?
| Hemorrhage | 1 | 2005 | 620 | 0.040 |
Why?
| Chronic Disease | 1 | 2006 | 1578 | 0.040 |
Why?
| Leukotriene C4 | 1 | 2000 | 12 | 0.040 |
Why?
| CD18 Antigens | 1 | 2000 | 33 | 0.040 |
Why?
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 2000 | 65 | 0.040 |
Why?
| Glasgow Coma Scale | 1 | 2020 | 153 | 0.040 |
Why?
| CD11 Antigens | 1 | 2000 | 30 | 0.040 |
Why?
| Drug Resistance, Microbial | 1 | 2020 | 66 | 0.040 |
Why?
| Costs and Cost Analysis | 1 | 2020 | 196 | 0.040 |
Why?
| Epithelial Cells | 1 | 2005 | 951 | 0.040 |
Why?
| Surveys and Questionnaires | 3 | 2021 | 4624 | 0.040 |
Why?
| Needs Assessment | 1 | 2021 | 314 | 0.040 |
Why?
| Oxidative Stress | 1 | 2005 | 1076 | 0.040 |
Why?
| Smoking | 1 | 2006 | 1383 | 0.040 |
Why?
| Flow Cytometry | 2 | 2017 | 1083 | 0.040 |
Why?
| Algorithms | 1 | 2006 | 1470 | 0.040 |
Why?
| Aftercare | 1 | 2001 | 186 | 0.040 |
Why?
| Hospitals, University | 1 | 2019 | 172 | 0.040 |
Why?
| NF-kappa B | 2 | 2018 | 641 | 0.040 |
Why?
| T-Lymphocytes | 1 | 2006 | 1737 | 0.040 |
Why?
| Mice, Knockout | 3 | 2012 | 2570 | 0.040 |
Why?
| Infection Control | 1 | 2020 | 135 | 0.040 |
Why?
| Adjuvants, Immunologic | 1 | 2000 | 206 | 0.040 |
Why?
| Injury Severity Score | 1 | 2020 | 499 | 0.040 |
Why?
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2018 | 2 | 0.040 |
Why?
| Linear Models | 1 | 2020 | 768 | 0.040 |
Why?
| Trauma Centers | 1 | 2020 | 362 | 0.040 |
Why?
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2018 | 36 | 0.040 |
Why?
| Family | 1 | 2022 | 589 | 0.040 |
Why?
| Mortality | 1 | 2019 | 287 | 0.040 |
Why?
| Victoria | 1 | 2017 | 15 | 0.040 |
Why?
| Antigens, CD | 1 | 2000 | 442 | 0.040 |
Why?
| History, 17th Century | 1 | 2017 | 15 | 0.040 |
Why?
| History, 16th Century | 1 | 2017 | 14 | 0.040 |
Why?
| History, 15th Century | 1 | 2017 | 11 | 0.040 |
Why?
| Recovery of Function | 1 | 2021 | 574 | 0.040 |
Why?
| Cross-Sectional Studies | 2 | 2021 | 4410 | 0.040 |
Why?
| History, Ancient | 1 | 2017 | 48 | 0.040 |
Why?
| United Arab Emirates | 1 | 2017 | 5 | 0.040 |
Why?
| History, Medieval | 1 | 2017 | 40 | 0.030 |
Why?
| Drug Therapy, Combination | 2 | 2012 | 951 | 0.030 |
Why?
| Critical Care Outcomes | 1 | 2016 | 12 | 0.030 |
Why?
| History, 21st Century | 1 | 2017 | 159 | 0.030 |
Why?
| Refugees | 1 | 2017 | 54 | 0.030 |
Why?
| Probability | 1 | 2017 | 289 | 0.030 |
Why?
| Lymphocyte Activation | 1 | 2000 | 1037 | 0.030 |
Why?
| Trauma Severity Indices | 1 | 2016 | 114 | 0.030 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2018 | 398 | 0.030 |
Why?
| Anxiety | 1 | 2022 | 840 | 0.030 |
Why?
| Pilot Projects | 1 | 2019 | 1373 | 0.030 |
Why?
| Uteroglobin | 1 | 2014 | 16 | 0.030 |
Why?
| Socioeconomic Factors | 1 | 2018 | 1079 | 0.030 |
Why?
| Cost-Benefit Analysis | 1 | 2017 | 544 | 0.030 |
Why?
| Chemokine CXCL2 | 1 | 2014 | 41 | 0.030 |
Why?
| Arachidonate 5-Lipoxygenase | 1 | 2014 | 45 | 0.030 |
Why?
| Rosuvastatin Calcium | 1 | 2014 | 17 | 0.030 |
Why?
| Nitrates | 1 | 2014 | 72 | 0.030 |
Why?
| MAP Kinase Kinase 4 | 1 | 2014 | 23 | 0.030 |
Why?
| Nitrites | 1 | 2014 | 75 | 0.030 |
Why?
| Risk | 1 | 2017 | 812 | 0.030 |
Why?
| Creatine Kinase | 1 | 2014 | 75 | 0.030 |
Why?
| Quality Indicators, Health Care | 1 | 2017 | 287 | 0.030 |
Why?
| Epoxy Compounds | 1 | 2014 | 31 | 0.030 |
Why?
| Quality Improvement | 1 | 2021 | 950 | 0.030 |
Why?
| Chondroitin Sulfates | 1 | 2014 | 33 | 0.030 |
Why?
| Liver Failure | 1 | 2014 | 75 | 0.030 |
Why?
| Leukocyte Count | 1 | 2014 | 293 | 0.030 |
Why?
| Toll-Like Receptor 2 | 1 | 2014 | 110 | 0.030 |
Why?
| Kidney Function Tests | 1 | 2014 | 140 | 0.030 |
Why?
| Depression | 1 | 2022 | 1134 | 0.030 |
Why?
| Manikins | 1 | 2013 | 24 | 0.030 |
Why?
| Chromatography, Liquid | 1 | 2015 | 347 | 0.030 |
Why?
| Bronchial Spasm | 1 | 2013 | 4 | 0.030 |
Why?
| Cryptogenic Organizing Pneumonia | 1 | 2013 | 17 | 0.030 |
Why?
| Mass Spectrometry | 1 | 2016 | 633 | 0.030 |
Why?
| Contraindications | 1 | 2013 | 85 | 0.030 |
Why?
| Anesthesiology | 1 | 2013 | 35 | 0.030 |
Why?
| Tandem Mass Spectrometry | 1 | 2015 | 412 | 0.030 |
Why?
| Protein C Deficiency | 1 | 2012 | 2 | 0.030 |
Why?
| Connective Tissue Diseases | 1 | 2013 | 71 | 0.030 |
Why?
| Glucuronidase | 1 | 2012 | 42 | 0.030 |
Why?
| Cells, Cultured | 1 | 2000 | 3886 | 0.030 |
Why?
| Knowledge Bases | 1 | 2012 | 17 | 0.030 |
Why?
| Renal Insufficiency | 1 | 2014 | 137 | 0.030 |
Why?
| Intestinal Perforation | 1 | 2012 | 39 | 0.030 |
Why?
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2012 | 73 | 0.020 |
Why?
| Quality of Health Care | 1 | 2017 | 573 | 0.020 |
Why?
| Triage | 1 | 2014 | 199 | 0.020 |
Why?
| Disease Management | 1 | 2016 | 560 | 0.020 |
Why?
| Water-Electrolyte Balance | 1 | 2011 | 26 | 0.020 |
Why?
| Adoptive Transfer | 1 | 2012 | 195 | 0.020 |
Why?
| Endothelium | 1 | 2012 | 111 | 0.020 |
Why?
| Quality Assurance, Health Care | 1 | 2014 | 311 | 0.020 |
Why?
| Toll-Like Receptor 4 | 1 | 2014 | 287 | 0.020 |
Why?
| Cross-Over Studies | 1 | 2013 | 440 | 0.020 |
Why?
| Epistasis, Genetic | 1 | 2012 | 67 | 0.020 |
Why?
| General Surgery | 1 | 2013 | 127 | 0.020 |
Why?
| Cell Survival | 1 | 2014 | 1021 | 0.020 |
Why?
| Internal Medicine | 1 | 2013 | 211 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2017 | 2387 | 0.020 |
Why?
| Microbial Viability | 1 | 2011 | 79 | 0.020 |
Why?
| Arthroplasty, Replacement, Knee | 1 | 2014 | 246 | 0.020 |
Why?
| Superoxides | 1 | 2011 | 214 | 0.020 |
Why?
| Enzyme Activation | 1 | 2012 | 785 | 0.020 |
Why?
| Interleukin-8 | 1 | 2011 | 237 | 0.020 |
Why?
| Viruses | 1 | 2011 | 94 | 0.020 |
Why?
| Cell Separation | 1 | 2011 | 291 | 0.020 |
Why?
| Single-Payer System | 1 | 2009 | 2 | 0.020 |
Why?
| Survivors | 1 | 2013 | 411 | 0.020 |
Why?
| Species Specificity | 1 | 2011 | 542 | 0.020 |
Why?
| Disease-Free Survival | 1 | 2011 | 620 | 0.020 |
Why?
| Cell Death | 1 | 2011 | 323 | 0.020 |
Why?
| Administration, Inhalation | 1 | 2011 | 641 | 0.020 |
Why?
| Case-Control Studies | 1 | 2016 | 3004 | 0.020 |
Why?
| Nitric Oxide | 1 | 2014 | 823 | 0.020 |
Why?
| Information Dissemination | 1 | 2011 | 186 | 0.020 |
Why?
| Self Report | 1 | 2013 | 696 | 0.020 |
Why?
| Advisory Committees | 1 | 2010 | 208 | 0.020 |
Why?
| Drug Resistance, Bacterial | 1 | 2009 | 155 | 0.020 |
Why?
| Cell Line | 1 | 2014 | 2637 | 0.020 |
Why?
| Precision Medicine | 1 | 2012 | 337 | 0.020 |
Why?
| Microbial Sensitivity Tests | 1 | 2009 | 300 | 0.020 |
Why?
| Total Quality Management | 1 | 2008 | 61 | 0.020 |
Why?
| Ventilator Weaning | 1 | 2008 | 33 | 0.020 |
Why?
| Placebos | 1 | 2008 | 197 | 0.020 |
Why?
| Neutrophil Infiltration | 1 | 2008 | 96 | 0.020 |
Why?
| Capillary Permeability | 1 | 2008 | 139 | 0.020 |
Why?
| United States Food and Drug Administration | 1 | 2008 | 172 | 0.020 |
Why?
| Health Plan Implementation | 1 | 2008 | 132 | 0.020 |
Why?
| Interdisciplinary Communication | 1 | 2008 | 183 | 0.020 |
Why?
| Drug Industry | 1 | 2008 | 103 | 0.020 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2012 | 1140 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2011 | 1842 | 0.020 |
Why?
| Chemokines | 1 | 2008 | 216 | 0.020 |
Why?
| Acid-Base Equilibrium | 1 | 2007 | 29 | 0.020 |
Why?
| Umbilical Veins | 1 | 2006 | 58 | 0.020 |
Why?
| Cost Control | 1 | 2006 | 39 | 0.020 |
Why?
| CD8 Antigens | 1 | 2006 | 69 | 0.020 |
Why?
| Ketones | 1 | 2007 | 44 | 0.020 |
Why?
| Medical Audit | 1 | 2007 | 75 | 0.020 |
Why?
| Microcirculation | 1 | 2007 | 135 | 0.020 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 103 | 0.020 |
Why?
| Bacillus subtilis | 1 | 2006 | 58 | 0.020 |
Why?
| CD4 Antigens | 1 | 2006 | 123 | 0.020 |
Why?
| Information Management | 1 | 2006 | 15 | 0.020 |
Why?
| Cell Count | 1 | 2006 | 303 | 0.020 |
Why?
| Fluorescent Antibody Technique | 1 | 2006 | 397 | 0.020 |
Why?
| Genome-Wide Association Study | 1 | 2012 | 1177 | 0.020 |
Why?
| User-Computer Interface | 1 | 2006 | 140 | 0.020 |
Why?
| Interleukin-10 | 1 | 2006 | 299 | 0.010 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2012 | 1880 | 0.010 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2007 | 238 | 0.010 |
Why?
| Asthma | 1 | 2017 | 2029 | 0.010 |
Why?
| Inflammation Mediators | 1 | 2006 | 477 | 0.010 |
Why?
| Hypoglycemia | 1 | 2007 | 387 | 0.010 |
Why?
| Endothelium, Vascular | 1 | 2007 | 847 | 0.010 |
Why?
| Cardiotonic Agents | 1 | 2001 | 119 | 0.010 |
Why?
| Hypothermia, Induced | 1 | 2001 | 66 | 0.010 |
Why?
| Mass Screening | 1 | 2006 | 1006 | 0.010 |
Why?
| RNA, Messenger | 1 | 2006 | 2553 | 0.010 |
Why?
| Hypoglycemic Agents | 1 | 2007 | 1013 | 0.010 |
Why?
| Dopamine | 1 | 2001 | 236 | 0.010 |
Why?
| Anti-Inflammatory Agents | 1 | 2001 | 447 | 0.010 |
Why?
| Insulin | 1 | 2007 | 2080 | 0.010 |
Why?
|
|
Douglas's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|